Stock Track | Ardelyx Soars 7.72% Pre-Market on China Approval of Tenapanor for Hyperphosphatemia

Stock Track
02-26

Ardelyx Inc. (ARDX) shares surged 7.72% in pre-market trading on Wednesday after the company announced that its collaboration partner, Fosun Pharma, received approval from China's Center for Drug Evaluation for tenapanor (marketed as Wan Ti Le) to control serum phosphorus levels in dialysis patients with chronic kidney disease (CKD).

This approval triggers a $5 million milestone payment to Ardelyx from Fosun Pharma under their licensing agreement. Ardelyx is also eligible to receive additional developmental and commercialization milestones of up to $100 million, as well as tiered royalty payments on net sales ranging from the mid-teens to 20 percent.

Tenapanor, a first-in-class phosphate absorption inhibitor, has the potential to address a significant unmet need in China, where approximately 76% of over one million patients on maintenance hemodialysis suffer from hyperphosphatemia, and the rate of achieving target phosphate levels is low.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10